Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02490748
PHASE2

Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Sponsor: The First People's Hospital of Changzhou

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cervical cancer.

Official title: Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer

Key Details

Gender

FEMALE

Age Range

30 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2015-07

Completion Date

2040-06

Last Updated

2016-02-23

Healthy Volunteers

No

Conditions

Interventions

PROCEDURE

Radiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance

BIOLOGICAL

Cytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.